Glenmark to pay $30 million in an antitrust settlement in US over cholesterol drug pricing

The company in an exchange notification said that it has entered into a three-year deferred prosecution agreement, and if the company adheres to the terms of the agreement, including the payment of $30 million, payable in six installments, the DOJ will dismiss the pending superseding indictment.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news